Adhezion seals deal on more funds for series A
This article was originally published in Clinica
Executive Summary
Adhezion Biomedical, a Wyomissing, Pennsylvania-based developer of cyanoacrylate-based medical adhesives and antimicrobial sealants, has raised an additional $2.1m in series A financing, bringing the total investment received to $5.25m. The second tranche of funds came from Liberty Venture Partners. Adhezion’s flagship product is SurgiSeal, which is being introduced to European markets and is pending US FDA approval. Other products in the pipeline include DermaSeal, a woundcare product, and FloraSeal, an advancedantimicrobial sealant.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.